HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.5406
-0.0090 (-1.64%)
At close: Feb 27, 2026, 4:00 PM EST
0.5215
-0.0191 (-3.53%)
After-hours: Feb 27, 2026, 7:56 PM EST
HCW Biologics Employees
HCW Biologics had 36 employees as of December 31, 2024. The number of employees decreased by 9 or -20.00% compared to the previous year.
Employees
36
Change (1Y)
-9
Growth (1Y)
-20.00%
Revenue / Employee
$11,723
Profits / Employee
-$616,834
Market Cap
3.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 36 | -9 | -20.00% |
| Dec 31, 2023 | 45 | 1 | 2.27% |
| Dec 31, 2022 | 44 | 0 | - |
| Dec 31, 2021 | 44 | 4 | 10.00% |
| Mar 31, 2021 | 40 | - | - |
| Dec 31, 2020 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Scinai Immunotherapeutics | 31 |
| Dermata Therapeutics | 8 |
| Enveric Biosciences | 6 |
| Adial Pharmaceuticals | 5 |
| Oragenics | 5 |
| GRI Bio | 4 |
| Acurx Pharmaceuticals | 4 |
| XORTX Therapeutics | 3 |
HCWB News
- 11 days ago - HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 15 days ago - HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - GlobeNewsWire
- 3 months ago - HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - GlobeNewsWire
- 3 months ago - HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 4 months ago - HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 4 months ago - HCW Biologics to Participate in the 2025 Maxim Growth Summit - GlobeNewsWire
- 5 months ago - HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program - GlobeNewsWire
- 5 months ago - HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing - GlobeNewsWire